Development Of Patient-Derived Xenograft (Pdx) Models For Small Cell Lung Cancer (Sclc) As A Preclinical Platform For Drug Development

Small cell lung cancer comprises 15-20% of all lung cancer cases, is very invasive with a high mortality rate. Although SCLC patients respond to chemotherapy, there is a high rate of recurrence with treated patients and those in advanced stage of the disease often have a refractory response to treatment. As such, the need for new treatment modalities is critical. In this work, we describe the development and characterization including histopathology, IHC and mutational analysis of 8 SCLC PDX models established from a collection of >300 small cell lung cancer specimens, many of which come from prior-treated and metastatic patients. We have also evaluated functional response of these models with in vivo pharmacology studies. Our data demonstrates the potential to use these unique PDX models in drug development for treatment of SCLC. Citation Format: Chelsea Mullins, Jill Ricono, Praveen Nair, Cyrus Mirsaidi, Thomas Broudy. Development of patient-derived xenograft (PDX) models for small cell lung cancer (SCLC) as a preclinical platform for drug development. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4209. doi:10.1158/1538-7445.AM2015-4209